Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | ADH5 | P11766 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21034046 | 0.80 | LTB4R2 (0.51) | ALDH1A1FTOLTB4R2 | |
| SCHEMBL15479756 | 0.80 | DHODH (0.48) | ALDH1A1FTOL3MBTL1DHODHPARP1 | |
| SCHEMBL10104417 | 0.80 | NOTUM (0.47) | ALDH1A1FTOLTB4R2HPGDNPSR1 | |
| SCHEMBL6530898 | 0.80 | ALDH1A1 (0.45) | ALDH1A1FTOLTB4R2MAPTHPGD | |
| SCHEMBL2645840 | 0.80 | KDM4E (0.47) | ALDH1A1FTOLTB4R2MAPTHPGD | |
| SCHEMBL31546405 | 0.80 | NOTUM (0.47) | ALDH1A1FTOLTB4R2HPGDNPSR1 | |
| SCHEMBL31546406 | 0.80 | FTO (0.49) | ALDH1A1FTOHPGDKMOGRIK1 | |
| SCHEMBL21634961 | 0.80 | ALDH1A1 (0.42) | ALDH1A1FTOLTB4R2MAPTHPGD | |
| SCHEMBL23869502 | 0.80 | ALDH1A1 (0.43) | ALDH1A1FTOLTB4R2MAPTHPGD | |
| SCHEMBL31546460 | 0.76 | FGFR1 (0.47) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | ALDH1A1 1188/4885FTO 1856/4885LTB4R2 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.